These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16738208)

  • 81. [Pharmacology of antiarrhythmia agents: the new aspects].
    Kaverina NV; Chichkanov GG
    Eksp Klin Farmakol; 2003; 66(2):46-52. PubMed ID: 12962048
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The force-frequency relation in normal and failing heart.
    Faggiano P; Colucci WS
    Cardiologia; 1996 Dec; 41(12):1155-64. PubMed ID: 9031531
    [No Abstract]   [Full Text] [Related]  

  • 83. Effect of Mn2+ on neonatal and adult rat heart: initial depression and late augmentation of contractile force.
    Agata N; Tanaka H; Shigenobu K
    Eur J Pharmacol; 1992 Nov; 222(2-3):223-6. PubMed ID: 1451734
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Positive inotropic effect of porcine left ventricular extract on canine ventricular muscle.
    Navaratnam S; Chau T; Agbanyo M; Bose D; Khatter JC
    Br J Pharmacol; 1990 Oct; 101(2):370-4. PubMed ID: 2257439
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
    Garcia-Gonzalez MJ; Dominguez-Rodriguez A; Ferrer-Hita J
    Int J Cardiol; 2006 Jun; 110(3):420. PubMed ID: 16309757
    [No Abstract]   [Full Text] [Related]  

  • 86. [Recent findings on the dromotropic actions of the class III antiarrhythmic agents].
    Maruyama T; Ito H
    Nihon Yakurigaku Zasshi; 2002 Nov; 120(5):335-42. PubMed ID: 12491809
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization.
    Stevenson LW
    Circulation; 2003 Jul; 108(3):367-72. PubMed ID: 12876135
    [No Abstract]   [Full Text] [Related]  

  • 88. [Study of the relation between the electromolecular characteristics of digitalis compounds and their pharmacological action].
    del Valle Mondragón L; Torres Narváez JC; Zarco Olvera G; Tenorio López FA; Pastelín Hernández G
    Arch Cardiol Mex; 2003; 73(1):11-7. PubMed ID: 12820489
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Effects of prolyl-valine on electrical activities of rat hearts in situ and its antiarrhythmic action (author's transl)].
    Liu TF; Wei JH
    Zhonghua Xin Xue Guan Bing Za Zhi; 1981 Dec; 9(4):311-3. PubMed ID: 7341201
    [No Abstract]   [Full Text] [Related]  

  • 90. [Racemates and enantiomers of basic, substituted 5-phenylhydantoins, synthesis and anti-arrhythmic action].
    Knabe J; Baldauf J; Ahlhelm A
    Pharmazie; 1997 Dec; 52(12):912-9. PubMed ID: 9480456
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Strain softening behaviour in nonviable rat right-ventricular trabeculae, in the presence and the absence of butanedione monoxime.
    Kirton RS; Taberner AJ; Nielsen PM; Young AA; Loiselle DS
    Exp Physiol; 2004 Sep; 89(5):593-604. PubMed ID: 15258118
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [Inotropic action of isoprenaline on intact and reserpinized rat hearts with repeated administrations of the drug].
    Kozlov AG; Shmigol' AV
    Fiziol Zh (1978); 1984; 30(2):232-4. PubMed ID: 6724031
    [No Abstract]   [Full Text] [Related]  

  • 93. Mechanisms and use of calcium-sensitizing agents in the failing heart.
    Kass DA; Solaro RJ
    Circulation; 2006 Jan; 113(2):305-15. PubMed ID: 16418450
    [No Abstract]   [Full Text] [Related]  

  • 94. [Electropharmacological properties of class III antiarrhythmic drugs].
    Kanno M; Tohse N; Nakaya H
    Jpn Circ J; 1994; 58 Suppl 4():1232-7. PubMed ID: 7699765
    [No Abstract]   [Full Text] [Related]  

  • 95. Letter regarding article by von Lewinski et al, "Insulin causes [Ca2+]i-dependent and [Ca2+]i-independent positive inotropic effects in failing human myocardium".
    Hsu CH; Lin CI; Wei J
    Circulation; 2005 Dec; 112(25):e367; author reply e367. PubMed ID: 16365202
    [No Abstract]   [Full Text] [Related]  

  • 96. [Pharmacological correction of impaired tolerance to strophanthin in a model of cardiac decompensation].
    Galenko-Iaroshevskiĭ PA; Lemkina SM; Kostin IaV
    Biull Eksp Biol Med; 1994 May; 117(5):487-90. PubMed ID: 9296697
    [No Abstract]   [Full Text] [Related]  

  • 97. Antiarrhythmic activity of 4,6-di(het)aryl-5-nitro-3,4-dihydropyrimidin-(1H)-2-ones and its effects on arterial pressure in rats.
    Bryzgalov AO; Dolgikh MP; Sorokina IV; Tolstikova TG; Sedova VF; Shkurko OP
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1418-20. PubMed ID: 16321526
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Destabilization and early termination of spiral-wave reentry by a class III antiarrhythmic agent, nifekalant, in a perfused two-dimensional layer of rabbit ventricular myocardium.
    Circ Res; 2006 Feb; 98(3):e28. PubMed ID: 16357308
    [No Abstract]   [Full Text] [Related]  

  • 99. An analysis of the effect of pH, procaine cation, nonionized procaine and procaine ethylchloride cation upon cardiac conduction time, stimulation threshold, amplitude of contraction and the relationship of these parameters to antiarrhythmic activity.
    BAIRD WM; HARDMAN HF
    J Pharmacol Exp Ther; 1961 Jun; 132():382-91. PubMed ID: 13686012
    [No Abstract]   [Full Text] [Related]  

  • 100. Metabolic aspects of the positive inotropic action of fluoride on rat ventricle.
    COVIN JM; BERMAN DA
    J Pharmacol Exp Ther; 1959 Feb; 125(2):137-41. PubMed ID: 13631613
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.